2025 CMCR Symposium Exploring paradoxes along the gut-brain axis

The 2025 CMCR Symposium will highlight the very best translational, clinical, and public health research on cannabis, cannabinoids and the gut-brain axis, exploring paradoxes that have affected trust in the use of cannabinoids as therapeutics. For example, cannaboids as a potential cause of and treatment for psychosis, or as a treatment for and cause of nausea and vomiting. The symposium will bring clarity to these apparent contradictions and promote an expansion of investigation into these important areas of research through talks by context experts and live discussion and audience Q&A.

1. Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in conditions affecting healthy aging.
2. Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.
3. Evaluate the biological mechanisms by which cannabinoids and the endocannabinoid system function, and assess their potential impact on cancer biology.
4. Critically assess research methods and apply tools and strategies to conduct rigorous clinical and translational studies on cannabinoids.
5. Assess the use of cannabinoids in clinical populations and analyze their impact on public health and safety.
6. Review and discuss research priorities in cannabinoid science.
7. Facilitate a comprehensive research training experience for trainees, early-stage investigators, and established researchers interested in cannabis research.
8. Analyze the biological mechanisms of action of cannabinoids and the endocannabinoid system, and relate them to their potential therapeutic roles in the treatment of dementia.

AAPA: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 6.00 hours of Category 1 credit for completing this program.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credits™ issued by organizations accredited by the ACCME. For the purpose of relicensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credits™ (report up to 6.00 hours of credit and list "CME Category 1" as the provider number). 

Cultural & Linguistic Competency and Implicit Bias: Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content.  Additional information and resources are available on the UC San Diego CME website. 

All persons in a position to control the content of accredited education must disclose all financial relationships held with ineligible companies, prior to assuming their role in the accredited activity. Those relationships deemed relevant to the education, are mitigated prior to the activity.

CME staff, meeting planners, peer reviewers, editorial staff, and CME committee reviewers, do not have any relevant financial relationships with ACCME-defined ineligible companies.

Mitigation of Relevant Financial Relationships

The UC San Diego School of Medicine adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education.